1. Home
  2. KPRX vs BQ Comparison

KPRX vs BQ Comparison

Compare KPRX & BQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KPRX
  • BQ
  • Stock Information
  • Founded
  • KPRX 1998
  • BQ 2008
  • Country
  • KPRX United States
  • BQ China
  • Employees
  • KPRX N/A
  • BQ N/A
  • Industry
  • KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • BQ Other Specialty Stores
  • Sector
  • KPRX Health Care
  • BQ Consumer Discretionary
  • Exchange
  • KPRX Nasdaq
  • BQ Nasdaq
  • Market Cap
  • KPRX 8.7M
  • BQ 7.1M
  • IPO Year
  • KPRX N/A
  • BQ 2020
  • Fundamental
  • Price
  • KPRX $2.71
  • BQ $3.02
  • Analyst Decision
  • KPRX Strong Buy
  • BQ
  • Analyst Count
  • KPRX 1
  • BQ 0
  • Target Price
  • KPRX $10.00
  • BQ N/A
  • AVG Volume (30 Days)
  • KPRX 80.3K
  • BQ 29.3K
  • Earning Date
  • KPRX 08-08-2025
  • BQ 10-28-2025
  • Dividend Yield
  • KPRX N/A
  • BQ N/A
  • EPS Growth
  • KPRX N/A
  • BQ N/A
  • EPS
  • KPRX N/A
  • BQ N/A
  • Revenue
  • KPRX N/A
  • BQ $64,617,102.00
  • Revenue This Year
  • KPRX N/A
  • BQ N/A
  • Revenue Next Year
  • KPRX N/A
  • BQ N/A
  • P/E Ratio
  • KPRX N/A
  • BQ N/A
  • Revenue Growth
  • KPRX N/A
  • BQ N/A
  • 52 Week Low
  • KPRX $2.25
  • BQ $1.62
  • 52 Week High
  • KPRX $4.18
  • BQ $9.89
  • Technical
  • Relative Strength Index (RSI)
  • KPRX 48.49
  • BQ 60.01
  • Support Level
  • KPRX $2.67
  • BQ $2.69
  • Resistance Level
  • KPRX $2.90
  • BQ $3.47
  • Average True Range (ATR)
  • KPRX 0.14
  • BQ 0.22
  • MACD
  • KPRX 0.01
  • BQ 0.04
  • Stochastic Oscillator
  • KPRX 39.13
  • BQ 57.14

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

About BQ Boqii Holding Limited representing

Boqii Holding Ltd operates in the business of selling pet products through online stores. The store provides pet foods, health products, pet grooming products, pet bathing products, pet toys, fish tank, aquatic fertilizer, temperature control equipment, oxygen pump and other related products. Also, the company sells its products through offline channels to pet stores and hospitals.

Share on Social Networks: